Please Wait
Applying Filters...
menu
    • menu
    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Lupin Manufacturing Solutions – delivering high-quality APIs & end-to-end CDMO services for faster, cost-effective drug development.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    An Enquiry

    Menu

    Desidustat

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    MARKET PLACE

    PharmaCompass
    $ API Ref.Price (USD/KG) : 19,850Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Zydus Gets USFDA Orphan Drug Designation For Desidustat
    Zydus Gets USFDA Orphan Drug Designation For Desidustat

    07 Feb 2026

    // INDPHARMAPOST

    https://www.indianpharmapost.com/drug-approval/zydus-receives-usfda-odd-for-desidustat-for-the-treatment-of-sickle-cell-disease-19058

    INDPHARMAPOST
    07 Feb 2026
    Share Share
    Zydus Secures USFDA Orphan Drug Status For Desidustat In Sickle
    Zydus Secures USFDA Orphan Drug Status For Desidustat In Sickle

    06 Feb 2026

    // ECONOMICTIMES

    https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/zydus-desidustat-gets-usfda-orphan-drug-status-for-sickle-cell-disease/articleshow/127978743.cms

    ECONOMICTIMES
    06 Feb 2026
    Share Share
    Zydus' Desidustat Receives USFDA Orphan Drug Designation
    Zydus' Desidustat Receives USFDA Orphan Drug Designation

    06 Feb 2026

    // EXPRESSPHARMA

    https://www.expresspharma.in/usfda-grants-orphan-drug-designation-to-zydus-desidustat-for-sickle-cell-disease/

    EXPRESSPHARMA
    06 Feb 2026
    Share Share
    Zydus Gets FDA Orphan Drug Designation For Desidustat
    Zydus Gets FDA Orphan Drug Designation For Desidustat

    06 Nov 2025

    // INDPHARMAPOST

    https://www.indianpharmapost.com/drug-approval/zydus-receives-fdas-odd-for-desidustat-for-the-treatment-of-beta-thalassemia-18153

    INDPHARMAPOST
    06 Nov 2025
    Share Share
    Zydus and ICMR Start Phase 2 Trial of Desidustat for Sickle Cell
    Zydus and ICMR Start Phase 2 Trial of Desidustat for Sickle Cell

    15 Oct 2024

    // INDPHARMAPOST

    https://www.indianpharmapost.com/news/zydus-and-icmr-initiate-a-phase-2-trial-of-desidustat-in-patients-with-sickle-cell-disease-16318

    INDPHARMAPOST
    15 Oct 2024
    Share Share
    Zydus gets DCGI nod for drug to treat anaemia linked with kidney disease
    Zydus gets DCGI nod for drug to treat anaemia linked with kidney disease

    07 Mar 2022

    // BUSINESS-STANDARD

    https://www.business-standard.com/article/companies/zydus-gets-dcgi-nod-for-drug-to-treat-anaemia-linked-with-kidney-disease-122030700301_1.html

    BUSINESS-STANDARD
    07 Mar 2022
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.